Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 17;10(6):e0129550.
doi: 10.1371/journal.pone.0129550. eCollection 2015.

Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000

Marie-Anne Vandenhende  1 , Caroline Roussillon  2 , Sandrine Henard  3 , Philippe Morlat  1 , Eric Oksenhendler  4 , Hugues Aumaitre  5 , Aurore Georget  2 , Thierry May  3 , Eric Rosenthal  6 , Dominique Salmon  7 , Patrice Cacoub  8 , Dominique Costagliola  9 , Geneviève Chêne  2 , Fabrice Bonnet  1 ; ANRS EN20 Mortalité 2010 study group
Affiliations

Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000

Marie-Anne Vandenhende et al. PLoS One. .

Abstract

Objectives: The current study aimed at describing the distribution and characteristics of malignancy related deaths in human immunodeficiency virus (HIV) infected patients in 2010 and at comparing them to those obtained in 2000 and 2005.

Methods: Data were obtained from three national surveys conducted in France in 2010, 2005 and 2000. The underlying cause of death was documented using a standardized questionnaire fulfilled in French hospital wards involved in the management of HIV infection.

Results: Among the 728 deaths reported in 2010, 262 were cancer-related (36%). After a significant increase from 28% in 2000 to 33% in 2005 and 36% in 2010, cancers represent the leading cause of mortality in HIV infected patients. The proportion of deaths attributed to non-AIDS/non-hepatitis-related cancers significantly increased from 2000 to 2010 (11% of the deaths in 2000, 17% in 2005 and 22% in 2010, p<0.001), while those attributed to AIDS-defining cancers decreased during the same period (16% in 2000, 13% in 2005 and 9% in 2010, p = 0.024). Particularly, the proportion of respiratory cancers significantly increased from 5% in 2000 to 6% in 2005 and 11% in 2010 (p = 0.004). Lung cancer was the most common cancer-related cause of death in 2010 (instead of non-Hodgkin lymphoma so far) and represented the leading cause of death in people living with HIV overall.

Conclusions: Cancer prevention (especially smoking cessation), screening strategies and therapeutic management need to be optimized in HIV-infected patients in order to reduce mortality, particularly in the field of respiratory cancers.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests: CR, AG, EO and DS had no conflicts of interest to declare. M-AV has received honoraria or travel/meeting expenses from Gilead, Janssen-Cilag and Merck Sharp & Dohme-Chibret. SH has received travel/meeting expenses from Pfizer. PM has received honoraria or travel/meeting expenses from Bristol-Myers Squibb, Gilead, Janssen-Cilag, Merck Sharp & Dohme-Chibret and ViiV Healthcare. HA has received honoraria or travel/meeting expenses from Gilead, Janssen-Cilag and Merck Sharp & Dohme-Chibret. TM has received honoraria from Janssen Cilag and ViiV Healthcare. ER has received honoraria from Amgen, Bristol-Myers Squibb, Gilead, Janssen Cilag, Merck Sharp & Dohme-Chibret and Roche. PC has received honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen-Cilag, Merck Sharp & Dohme-Chibret, Roche, Servier, and Vifor. DC has received honoraria from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme-Chibret and Roche. GC has received consulting fees from Roche and has received travel grant from Lundbeck. GC has had scientific responsibilities in projects receiving specific grant supports that are managed through her Institution or a non-profit society: from the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the European Commission (Framework Program 7), U.K. Medical Research Council, U.S. National Institute of Health (NIH), Fondation Plan Alzheimer, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Chiron, Fit Biotech LTD, Gilead Sciences, GlaxoSmithKline, Jansen Cilag, Merck Sharp & Dohme-Chibret, Pfizer, Roche, Tibotec, ViiV Healthcare. GC serves as Academic Editor of PLOS ONE and is on the editorial board of BMC Infectious Diseases Journal. FB has received honoraria or travel/meeting expenses from Gilead, Janssen Cilag, Merck Sharp & Dohme-Chibret and ViiV Healthcare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Location of cancers (N = 268) among HIV-infected adults with underlying cause of death being cancer (N = 262), Mortalité 2010 survey, France.
See this image and copyright information in PMC

References

    1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860. - PubMed
    1. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97: 425–432. - PubMed
    1. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148: 728–736. - PubMed
    1. Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52: 611–622. 10.1097/QAI.0b013e3181b327ca - DOI - PMC - PubMed
    1. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. (2009) Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 48: 633–639. - PubMed

Publication types